Inhibition of simian varicella virus infection of monkeys by 1-(2-deoxy-2- fluoro-1-beta-D-arabinofuranosyl)-5-ethyluracil (FEAU) and synergistic effects of combination with human recombinant interferon-beta.
1-(2-Deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-ethyluracil (FEAU) has been shown to be a highly effective inhibitor of Simian varicella virus infection in African green monkeys. Administration of FEAU by either intravenous injection or gavage at doses as low as 1 mg/kg/day prevented the development of rash and reduced viremia. The effective dose could be further reduced to 0.2 mg/kg/day when administered in combination with a sub-effective dose of human recombinant interferon-beta. No evidence of toxicity was seen in monkeys treated for 10 days with FEAU doses of 10 mg/kg/day when they were monitored by hematology and clinical chemistry tests and by clinical observations.
Soike
K F
KF
Delta Regional Primate Research Center, Covington, LA 70433.
Chou
T C
TC
Fox
J J
JJ
Watanabe
K A
KA
Gloff
C A
CA
D000257:Adenoviridae Infections / Q000517:prevention & control*; D000261:Adenoviruses, Simian / Q000187:drug effects; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D001086:Arabinofuranosyluracil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D002522:Chlorocebus aethiops; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006801:Humans; D007275:Injections, Intravenous; D007370:Interferon Type I / Q000008:administration & dosage / Q000494:pharmacology*; D011994:Recombinant Proteins; D014529:Uridine / Q000031:analogs & derivatives*; D014766:Viremia / Q000188:drug therapy
D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins; D001086:Arabinofuranosyluracil; C052341:1-(2-deoxy-2-fluoroarabinofuranosyl)-5-ethyluracil; D014529:Uridine